Cipla plans expansion, aims to launch at least one product in US every year

Cipla, a prominent name in the respiratory segment in India, is expecting its next leg of growth from the international market. Having launched products in the segment in the international market, it added $70-100 million in revenues last financial year. Cipla now aims to launch at least one product in the US (in the segment) every year from next year.

In India, Cipla already enjoys a 67-68 per cent share of the respiratory drugs market, and the company says there is potential for a 14-15 per cent growth as the market is under-penetrated. The overall respiratory market is expected to clock 12-13 per cent growth.

Cipla Chief Executive Officer (CEO) Umang Vohra said the firm was planning to work closely with diagnostic centres to boost the detection rates of respiratory illnesses.

“There are an estimated 90 million patients with respiratory illnesses in India of whom only 30 million are diagnosed. Less than 10 million actually get proper treatment,” he said. The burden of respiratory illnesses is as big as diabetes in India.